OptimizeRx Corporation (NASDAQ:OPRX) Q1 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed signals: while revenue growth and improved EBITDA are positive, the decrease in gross margin and lack of share repurchase plan are concerning. The Q&A highlighted management's confidence, but also some unclear responses about revenue specifics. The company's strategic focus on market share expansion and digital advertising is promising, yet supply chain challenges and competitive pressures persist. The net revenue retention rate is strong, but guidance on future margins remains uncertain. Overall, the lack of a clear positive catalyst suggests a neutral stock price movement in the short term.
Key Financial Performance
Revenue $21.9 million, an increase of 11% year-over-year from $19.7 million.
Gross Margin 60.9%, a decrease from 62% year-over-year, primarily due to product and channel partner mix.
Operating Expenses Decreased by $1.8 million year-over-year, primarily driven by stock-based compensation and cost savings implemented last year.
Net Loss $2.2 million or $0.12 per share, improved from a net loss of $6.9 million or $0.38 per share year-over-year.
Non-GAAP Net Loss $1.5 million or $0.08 per diluted share, improved from a non-GAAP net loss of $2 million or $0.11 per diluted share year-over-year.
Adjusted EBITDA $1.5 million, compared to a loss of $0.3 million in Q1 2024.
Operating Cash Flow $3.9 million for the first quarter.
Cash Balance $16.6 million at the end of the quarter, up from $13.4 million on December 31, 2024.
Debt Balance $33.8 million, with $6.2 million of principal paid off through the first quarter.
Committed Contracted Revenue Exceeds $70 million, a greater than 25% improvement year-over-year.
Average Revenue per Top 20 Pharmaceutical Manufacturer Approximately $3 million, representing 63% of business in Q1 2025.
Net Revenue Retention Rate 114%.
Revenue per FTE $710,000, up from $641,000 in Q1 2024.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Market Expansion: We are seeing early momentum in our transition to a subscription-based model, with over 5% of our projected annual revenue already converted to subscription contracts for 2025.
Market Positioning: Our unique position has allowed us to develop the broadest suite of solutions in the market, empowering us to meet the diverse and evolving needs of our customers across every stage of the product life cycle.
Operational Efficiency: Adjusted EBITDA came in at $1.5 million, an improvement of nearly $2 million year-over-year during what is typically our seasonally weakest quarter.
Cost Management: Operating expenses for the quarter ended March 31, 2025, decreased $1.8 million year-over-year, primarily driven by stock-based compensation and cost savings implemented last year.
Strategic Shift: A key focus for the company will be drawing greater attention to our reach and scalability, while positioning ourselves as a strategic partner in addressing some of the most critical commercialization challenges facing pharma today.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Issues: Despite media coverage related to initiatives being implemented by the new administration, there are currently no significant headwinds directly impacting the business.
Supply Chain Challenges: The company is navigating an increasingly complex dynamic in the digital pharma marketing landscape, which may present supply chain challenges.
Competitive Pressures: The industry is undergoing a significant shift, and the company must adapt to remain competitive in a rapidly evolving market.
Economic Factors: The company is closely monitoring pharma leading indicators and engaging with clients to mitigate potential economic impacts.
Debt Management: The company has a debt balance of $33.8 million, which could pose a risk if not managed effectively.
Gross Margin Decline: Gross margin decreased from 62% to 60.9%, primarily due to product and channel partner mix, indicating potential challenges in maintaining profitability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Q1 revenues increased 11% year-over-year to $21.9 million.
Adjusted EBITDA: Adjusted EBITDA came in at $1.5 million, an improvement of nearly $2 million year-over-year.
Contracted Revenue: Contracted revenue continues to increase to more than 20% year-over-year.
Subscription Model Transition: Over 5% of projected annual revenue already converted to subscription contracts for 2025.
Rule of 40 Performance: Goal of achieving Rule of 40 performance in the coming years.
Market Positioning: Positioning as a strategic partner to address commercialization challenges in pharma.
Revenue Guidance: Increasing guidance for the year, expecting revenue between $101 million and $106 million.
Adjusted EBITDA Guidance: Adjusted EBITDA expected to be between $13 million and $15 million.
Market Share Expansion: Positioned to capture greater market share and expand pharma's digital spend.
Cash Position: Cash balance at the end of the quarter was $16.6 million.
Debt Management: Debt balance currently stands at $33.8 million, with $6.2 million of principal paid off.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: None
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How real-time is the feedback from your sales team regarding market conditions, and have you seen any hesitation from customers?
A:We’ve not seen really any pullback from our clients. We are getting real-time information and updates, and what we have seen is clients leaning in and trying to drive harder at these markets.
Q:Can you explain how moving to subscription-based revenue impacts revenue recognition and margins?
A:It spreads revenue over a 12-month period and is accretive to us because we keep most of that revenue and the cost of sales is low.
Q:What is the gross margin profile of the company going forward?
A:We’re working on increasing gross margins above the low 60% mark, but currently, the portfolio makeup is causing some dilution.
Q:Can you confirm the committed revenue and visibility for the year?
A:Yes, it’s north of 80% visibility currently, which is up from 60% last year.
Q:What percentage of revenue is represented by the data business?
A:We don’t break it out that way.
Q:Is there any further headwinds expected in the second half regarding NRR?
A:NRR is expected to end around 100% by the end of the year.
Q:Can you discuss the OpEx run rate and leverage as the top line grows?
A:We’re at a good run rate now and don’t expect to take more out or add more.
Q:Can you provide more details on the pipeline and win rates?
A:Pipeline continues to grow, and we’re winning more due to improved audience quality and data.
Q:Are the subscription deals multiyear or one-year arrangements?
A:Currently, they’re one-year evergreen arrangements.
Q:Does the high end of revenue guidance correlate with the high end of EBITDA?
A:It’s less about investing more to get to the top end; it’s more about gross margin dynamics.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the percentage of revenue represented by the data business, stating they do not break it out that way. Additionally, there was a lack of clarity regarding the impact of new business on gross margins and the specifics of the pipeline and win rates.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO Mr
DAAP neighborhood
DTC OptimizeRx
DTC service
KPIs pharmaceutical
KPIs progress
Marion Odence
Momentum revenue
Mr afternoon
Odence Ford
OptimizeRx CFO
OptimizeRx dynamic
OptimizeRx value
Rule KPIs
Rule end
Stelmakh detail
Transcript expectation
abandonment interoperability
ability need
addition medium
administration headwind
advantage edge
afternoon Conference
afternoon Investor
afternoon call
afternoon result
afternoon today
allocation
challenge pharma
dynamic pharma
expectation afternoon
focus
headwind pharma
loss share
pharma indicator
pharma marketing
pharma spend
pharma today
release afternoon
script lift
share month
size pharma
OPRX Transcript
OptimizeRx Corporation (OPRX) Q4 2025 Earnings Call Transcript
Positive3-5
The earnings call presents a generally positive outlook with strong financial performance, strategic market positioning, and optimistic guidance. Despite some concerns about contract durations and cautious spending by large pharma companies, management's focus on AI, debt repayment, and targeting mid-tier manufacturers is promising. The Q&A session reveals conservative client behavior but indicates normalization and growth opportunities. The company's strategic initiatives, including EHR partnerships and AI investments, support a positive sentiment, suggesting a stock price increase of 2% to 8% over the next two weeks.
OptimizeRx Corporation (OPRX) Q3 2025 Earnings Call Transcript
Positive11-7
The earnings call and Q&A reveal strong financial performance and strategic growth initiatives. The company reported increased revenue per top clients, high net revenue retention, and improved operational efficiency. Positive guidance for 2025 and promising initial 2026 projections enhance market confidence. Despite slight declines in Q4 guidance, the company’s conservative approach and focus on contracted revenue provide transparency. The strategic partnership with Lamar Advertising, though in pilot phase, hints at future growth potential. Overall, these factors suggest a positive stock price movement in the near term.
OptimizeRx Corporation (OPRX) Q2 2025 Earnings Call Transcript
Positive8-8
The earnings call reflects a strong financial performance with increased revenue guidance, improved EBITDA, and effective debt management. Despite some concerns about managed service revenue not continuing, the company's operational efficiency and growth in mid-cap and small businesses are positive indicators. The Q&A section highlighted management's confidence in maintaining current growth without increasing OpEx significantly. Overall, the financial health, strategic positioning, and optimistic guidance suggest a positive stock price movement in the near term.
OptimizeRx Corporation (NASDAQ:OPRX) Q1 2025 Earnings Call Transcript
Unknown5-13
The earnings call reveals mixed signals: while revenue growth and improved EBITDA are positive, the decrease in gross margin and lack of share repurchase plan are concerning. The Q&A highlighted management's confidence, but also some unclear responses about revenue specifics. The company's strategic focus on market share expansion and digital advertising is promising, yet supply chain challenges and competitive pressures persist. The net revenue retention rate is strong, but guidance on future margins remains uncertain. Overall, the lack of a clear positive catalyst suggests a neutral stock price movement in the short term.
OPRX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
